Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

Adrenoleukodystrophy: full-pipeline trial registry

3 of 7 indexed Adrenoleukodystrophy trials are currently recruiting.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Adrenoleukodystrophy: 7 US clinical trials tracked, 3 recruiting.

Adrenoleukodystrophy is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Masonic Cancer Center, University of Minnesota, running 2 of these trials.

Enrollment posture brief

Registry condition adrenoleukodystrophy

OPEN 3 | RECR 43% | LATE 2 | EARLY 3 | RANK #2497 | SPON 2

Nearest open-share peer: Advanced Solid Malignancies (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Adrenoleukodystrophy (this)43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Adrenoleukodystrophy

Adrenoleukodystrophy lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Adrenoleukodystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Adrenoleukodystrophy is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Adrenoleukodystrophy research.

    Masonic Cancer Center, University of Minnesota accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Adrenoleukodystrophy enrolment sits around 85 participants.

    Median target enrolment is 85 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.

  4. Adrenoleukodystrophy research is mostly interventional.

    5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Adrenoleukodystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cholic Acids Drug
1 trials
Busulfan, Cyclophosphamide, Antithymocyte Globulin Drug
1 trials
Human Placental Derived Stem Cell Drug
1 trials
Pramipexole Drug
1 trials
DUOC-01 Biological
1 trials
Stem Cell Transplant Procedure
1 trials
Biospecimen Sample Collection Other
1 trials
Medical Record Abstraction Other
1 trials

US sites by state

Facility locations filed on Adrenoleukodystrophy trials. A trial with sites in several states counts in each.

Minnesota 3 trials
Ohio 2 trials
North Carolina 2 trials
Massachusetts 2 trials
Utah 1 trials
Texas 1 trials
Pennsylvania 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Adrenoleukodystrophy page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adrenoleukodystrophy condition card totals 7 registered trials; most-linked intervention Cholic Acids; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.